Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2024

Genmab — Oktober 2024

Planlagt Fastgjort Låst Flyttet Genmab
991 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #841

    Genmab kan se frem til øgede royalties fra Novartis, som slår forventningerne

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #842

      Og Novartis slår da også analytikerne på de fleste poster.

      Og regnskabets danske islæt - Genmab - kan da også glæde sig over, at salget af Kesimpta, der anvendes til behandling af sklerose, steg med 28 pct.

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #843

        Det samlede salg af Kesimpta endte i årets tredje kvartal på 838 mio. dollar mod ventet 823,9 mio. dollar ifølge estimater indsamlet af Bloomberg News.

        Genmab modtager 10 pct. af salget i royalties.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #844

          Genmab kan se frem til øgede royalties fra Novartis, som slår forventningerne https://proinvestor.com/investornyt/1234109/genmab-kan-se-frem-til-ogede-royalties-fra-novartis-som-slar-forventningerne

          1 Reply Last reply
          0
          • exitnuE Offline
            exitnuE Offline
            exitnu
            wrote on sidst redigeret af
            #845

            Godt nyt mht. Kesimpta ...

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #846

              novartis q3-2024-investor-presentation https://www.novartis.com/sites/novartis_com/files/q3-2024-investor-presentation.pdf

              1 Reply Last reply
              0
              • O Offline
                O Offline
                Oduk
                wrote on sidst redigeret af
                #847

                God formiddag, Jeg husker at der var en der lagde et link op til H2H undersøgelsen ville være færdig i udgang af oktober, men er der nogle som ved hvor længe der plejer at gå før vi ser disse data? Umiddelbart ville jeg jo mene at de skal udgives med det samme, men er der nogle som kan be- eller afkræfte dette?

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #848

                  "Primary completion" (som næsten altid er et estimat) betyder strengt taget ikke færdig en bestemt dato, men kan for eksempel betyde, at den sidste patient forventes behandlet på et givet tidspunkt. Det er meget forskelligt, hvor hurtigt efter data offentliggøres.

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #849

                    Da 'primary data' under alle omstændigheder ikke er de endelige data, så tror jeg ikke, at der er nogen pligt til at offentliggøre dem

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #850

                      Altså i al almindelighed. Her ved vi jo, at de kommer

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #851

                        Q3-2024-PFE-Earnings-Release Pizer Tivdak $34 (32 US, 2 international) https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-PFE-Earnings-Release-Final.pdf

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #852

                          Exclusive: Genmab lines up T cell engager pact with Revitope Oncology https://endpts.com/exclusive-genmab-lines-up-t-cell-engager-pact-with-revitope/ https://www.revitope.com/

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #853

                            3 targets, Genmab pays $9mn upfront with potential milestones up to $600mn, solid tumors

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bikube
                              wrote on sidst redigeret af
                              #854

                              Er Tivdak stadig kun i 3. line. ?

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #855

                                yes. and only US and since this summer Macau, (not yet in mainland China). i assume that is where the $
                                2mn international is from, or maybe off-label. EU and Japan submitted this year.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #856

                                  We are waiting to see if they will proceed with trials for head and neck cancer which was one of the goals for this year, but seems a bit less certain after a recent evasive
                                  remark by Klimovsky

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #857

                                    Where i first thought that maybe Pfizer would be less interested in furthere Tiso development, now it could certainly also be Genmab after the addition of the Profound bio portfolio. If they really think toxicity is less with those ADC's then it is with Tiso ,
                                    it may be smart to invest the money there...

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #858

                                      a few changes in the GEN1046 Safety Trial write up. Also completion dates delayed (again) by a year this time; I wonder, given that they already stopped recruiting early this year, could that mean that patients stay on the drug longer than expected? or how should we look at this? https://clinicaltrials.gov/study/NCT03917381?tab=history&a=35&b=36#version-content-panel

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bikube
                                        wrote on sidst redigeret af
                                        #859

                                        Thanks E L.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #860

                                          GEN1047 set to Active not recruiting at 179 actual patients vs 400 expected, so I guess that doesn't look good? Not a very big surprise , was expecting news this quarter, let's see if they can give an update next week
                                          https://clinicaltrials.gov/study/NCT05180474?tab=history&a=16&b=17#version-content-panel

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper